# NRIX catalysts: Nurix Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nrix/catalysts

> Nurix Therapeutics, Inc. (NRIX) has 4 upcoming catalysts. The next is the bexobrutideg primary completion, January 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Nurix Therapeutics, Inc. |
| Ticker | NRIX (Nasdaq) |
| SEC CIK | 1549595 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nrix |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2024 | [Zelebrudomide trial start](https://sec-api.dev/pdufa/zelebrudomide) | NRIX |  | completed | "•Re-initiated enrollment in NX-2127 Phase 1a/b trial: Following a decision in March 2024 in which the FDA lifted a manufacturing-related, partial clinical hold on the NX-2127 clinical trial, Nurix reinitiated enrollment in a dose escalation study within the current Phase 1a/1b trial, using its new chirally controlled drug product of NX-2127, a novel orally bioavailable bifunctional molecule that degrades BTK and the cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000005/nrix20250113form8-kex991jpm.htm)) |
| January 28, 2025 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000014/nrix-20250128xexx991.htm)) |
| April 8, 2025 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000053/nrix-20250408xexx991.htm)) |
| July 9, 2025 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000094/nrix-20250709xexx991.htm)) |
| Q4 2025 | [Bexobrutideg trial start](https://sec-api.dev/pdufa/bexobrutideg) | NRIX | relapsed or refractory B-cell malignancies | scheduled | ""Nurix is preparing to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL patients in the fourth quarter of 2025 and we have outlined our plans for potential accelerated approval with a single arm study as well as a confirmatory randomized control Phase 3 study for full approval," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000112/nrix-20251009xexx991.htm)) |
| Oct 2025 | [Bexobrutideg trial start](https://sec-api.dev/pdufa/bexobrutideg) | NRIX |  | completed | "We filed our first IND in December 2020, we currently have three drug candidates in ongoing Phase 1 trials, and we initiated a Phase 2 clinical trial for bexobrutideg in October 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000040/nrix-20260531.htm)) |
| October 9, 2025 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000112/nrix-20251009xexx991.htm)) |
| 2026 | [Zelebrudomide trial start](https://sec-api.dev/pdufa/zelebrudomide) | NRIX |  | scheduled | "In particular, we are currently conducting Phase 1 clinical trials for each of our lead drug candidates, bexobrutideg, zelebrudomide and NX-1607, and a Phase 2 clinical trial for bexobrutideg, and we expect to initiate a Phase 3 clinical trial for bexobrutideg in 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000040/nrix-20260531.htm)) |
| January 28, 2026 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000013/nrix-20260128xexx991.htm)) |
| mid-2026 | [Bexobrutideg trial start](https://sec-api.dev/pdufa/bexobrutideg) | NRIX | relapsed/refractory CLL | scheduled | "•Preparations continue for DAYBreak CLL-306, the global randomized Phase 3 confirmatory trial evaluating bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL following prior BTK inhibitor therapy with the dosing of the first patient anticipated in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/nrix-20260709xexx991.htm)) |
| April 8, 2026 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000024/nrix-20260408xexx991.htm)) |
| July 9, 2026 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/nrix-20260709xexx991.htm)) |
| Sep 2026 | [NX-1607 trial start](https://sec-api.dev/pdufa/nx-1607) | NRIX | microsatellite-stable colorectal cancer | completed | "Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with the first patient dosed in September 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/nrix-20261013xexx991.htm)) |
| October 12, 2026 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/nrix-20261013xexx991.htm)) |
| January 2028 | [Bexobrutideg primary completion](https://sec-api.dev/pdufa/bexobrutideg) | NRIX | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | scheduled | "NCT07221500 (A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Nurix Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221500)) |
| Jan to Apr 2028 | [Bexobrutideg topline data readout](https://sec-api.dev/pdufa/bexobrutideg) | NRIX | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | scheduled | "NCT07221500 (A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Nurix Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221500)) |
| October 2029 | [Bexobrutideg primary completion](https://sec-api.dev/pdufa/bexobrutideg) | NRIX | B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT07516093 (Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Nurix Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07516093)) |
| Oct 2029 to Jan 2030 | [Bexobrutideg topline data readout](https://sec-api.dev/pdufa/bexobrutideg) | NRIX | B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT07516093 (Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Nurix Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07516093)) |

## Drugs

- [Bexobrutideg](https://sec-api.dev/pdufa/bexobrutideg): relapsed or refractory b-cell malignancies, relapsed/refractory cll, Chronic Lymphocytic Leukemia (CLL), B-cell Lymphoma
- [NX-1607](https://sec-api.dev/pdufa/nx-1607): microsatellite-stable colorectal cancer
- [Zelebrudomide](https://sec-api.dev/pdufa/zelebrudomide): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nrix/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NRIX catalysts: Nurix Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nrix/catalysts

```bibtex
@misc{secapidev_companies_nrix_catalysts_20261116,
  title        = {NRIX catalysts: Nurix Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nrix/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nrix_catalysts_20261116","title":"NRIX catalysts: Nurix Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nrix/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
